Celera to Focus on Drug Discovery

This move will reduce the infrastructure built to support the whole-genome sequencing and the acquisition of customers for the Online/Information business.

The restructuring is designed to realign the organization with Celera's drug discovery strategy. This strategy is based on the identification and validation of therapeutic targets from proteomics, genomics, and bioinformatics; and the development of new biologics and small molecule drugs. All of Celera's therapeutic R&D activities will be consolidated under a new manager.

"We also plan to add downstream development capabilities to allow us to further advance selected compounds from our preclinical programs toward clinical trials,” said Kathy Ordonex, president of Celera Genomics.




Related Links:
Celera